Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report)’s stock price traded down 3.5% on Friday . The company traded as low as $16.14 and last traded at $16.50. 11,425 shares traded hands during trading, a decline of 95% from the average session volume of 208,577 shares. The stock had previously closed at $17.10.
Wall Street Analyst Weigh In
Several analysts recently issued reports on SION shares. TD Cowen assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating for the company. Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $32.00 price objective for the company. Finally, Guggenheim began coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $45.00 target price for the company.
Get Our Latest Stock Analysis on SION
Sionna Therapeutics Trading Down 12.4 %
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Articles
- Five stocks we like better than Sionna Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Use Stock Screeners to Find Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What to Know About Investing in Penny Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
